{"id":"fibrinolytic-twice-daily","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fibrinolytic drugs work by converting the inactive zymogen plasminogen into its active form, plasmin, a serine protease that degrades fibrin—the structural protein that stabilizes blood clots. This mechanism enables dissolution of existing thrombi in conditions such as acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. The twice-daily dosing regimen suggests a formulation designed for sustained or repeated fibrinolytic activity.","oneSentence":"Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:30:40.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction"},{"name":"Acute ischemic stroke"},{"name":"Pulmonary embolism"},{"name":"Deep vein thrombosis"}]},"trialDetails":[{"nctId":"NCT06887062","phase":"PHASE2","title":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-21","conditions":"Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis","enrollment":60},{"nctId":"NCT07095361","phase":"PHASE4","title":"Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-09","conditions":"Pleural Infection Bacterial, Pleural Infections, Pleural Infections and Inflammations","enrollment":270},{"nctId":"NCT06434324","phase":"NA","title":"Pleural Space Saline Irrigation in Addition to Standard Intrapleural Thrombolytic Therapy in Empyema/Complicated Parapneumonic Effusion","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-03-29","conditions":"Pleural Infection","enrollment":60},{"nctId":"NCT06660719","phase":"PHASE3","title":"Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2025-02-14","conditions":"Ischemic Stroke","enrollment":852},{"nctId":"NCT03167281","phase":"PHASE4","title":"Early Intrapleural TPA Instillation Versus Late","status":"WITHDRAWN","sponsor":"Prisma Health-Midlands","startDate":"2017-02-17","conditions":"Tissue Plasminogen Activator","enrollment":""},{"nctId":"NCT03213834","phase":"PHASE4","title":"Fibrinolytic Therapy Versus Medical Thoracoscopy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-09-14","conditions":"Pleural Diseases","enrollment":5},{"nctId":"NCT05005052","phase":"PHASE3","title":"Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities","status":"UNKNOWN","sponsor":"Value Outcomes Ltd.","startDate":"2021-11-25","conditions":"Chronic Venous Disease, Chronic Insufficiency Venous","enrollment":290},{"nctId":"NCT03873766","phase":"PHASE4","title":"Management of Pleural Space Infections","status":"COMPLETED","sponsor":"Swedish Medical Center","startDate":"2019-04-01","conditions":"Empyema, Pleural, Parapneumonic Effusion","enrollment":26},{"nctId":"NCT03583931","phase":"NA","title":"Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2018-07-26","conditions":"Parapneumonic Effusion, Empyema, Pleural, Coagulopathy","enrollment":10},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT03468933","phase":"PHASE4","title":"Fibrinolysis Compared to Thoracoscopy for Pleural Infection","status":"COMPLETED","sponsor":"Tulane University","startDate":"2017-11-01","conditions":"Pleural Infection, Empyema, Pleural Diseases","enrollment":32},{"nctId":"NCT02973139","phase":"NA","title":"Fibrinolysis Compared to Thoracoscopy for Pleural Infection","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-07-14","conditions":"Pleural Infection, Pleural Diseases","enrollment":32},{"nctId":"NCT02227368","phase":"PHASE2","title":"Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-10-20","conditions":"Peripheral Artery Disease (PAD)","enrollment":40},{"nctId":"NCT01597336","phase":"NA","title":"Treatment of Abdominal Abscesses With or Without Fibrinolysis","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2009-06","conditions":"Abdominal Abscess, Tissue Plasminogen Activator","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":326,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lytics twice daily","tPA twice daily"],"phase":"marketed","status":"active","brandName":"Fibrinolytic twice daily","genericName":"Fibrinolytic twice daily","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi. Used for Acute myocardial infarction, Acute ischemic stroke, Pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}